<DOC>
	<DOC>NCT00816452</DOC>
	<brief_summary>Patients with prostate cancer treated in outpatient clinics will be recruited by their urologist physician. Primary Objective: To evaluate the compliance in male patients with prostate cancer treated with Bisphosphonate and that suffered from Osteopenia/osteoporosis. Secondary objectives: To evaluate the compliance of family physicians to prescribe Bisphosphonate for patients upon recommendation by Urologists. To evaluate the overall number of patients treated by Bisphosphonate in the out-patient clinics, To evaluate incidence of osteopenia/osteoporosis in this study population.</brief_summary>
	<brief_title>Awareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Man with Prostate Cancer Men ≥70 years old or ≥60 years old treated by LHRH agonist for at least 2 years or Man who was diagnosed in the past with Osteopenia/osteoporosis Osteopenia/osteoporosis proven by bone density test. Creatinine clearance &lt; 30ml/min Hypercalcemia Actual treatment by Bisphosphonate or steroids Hypersensibility to Bisphosphonate or any contraindication to its use. Metastatic prostate Cancer Patients not suitable for compliance. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Male</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Osteoporosis in male with Prostate Cancer</keyword>
</DOC>